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Background and purpose: Recognizing the link between altered tumor metabolism and disease aggres-
siveness, this study aimed to identify associations between tumor metabolic profiles and therapeutic out-
come in locally advanced rectal cancer (LARC).
Materials and methods: Pretreatment tumor metabolic profiles from 54 LARC patients receiving
combined-modality neoadjuvant treatment and surgery were acquired by high-resolution magic angle
spinning magnetic resonance spectroscopy (HR MAS MRS). Metabolite concentrations were correlated
to TNM and the presence of disseminated tumor cells (DTC) at diagnosis, ypTN and tumor regression
grade (TRG) following neoadjuvant treatment, and progression-free survival (PFS).
Results: Pretreatment tumor metabolite concentrations showed no significant associations to TNM, DTC,
ypTN or TRG. In univariate regression analysis, high concentrations of glycine, creatine and myo-inositol
were significantly associated with poor PFS, with metastasis as main PFS event. In multivariate analysis,
high glycine concentration remained most significantly associated with poor PFS (hazard ratio = 4.4, 95%
confidence interval = 1.4–14.3, p = 0.008).
Conclusions: High tumor glycine concentration was identified as adverse prognostic factor for PFS in
LARC. In a patient population treated with curative intent but with metastatic disease as main PFS event
further investigations of glycine as early predictor of metastatic progression and therapeutic target are
warranted.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 118 (2016) 393–398
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Locally advanced rectal cancer (LARC) encompasses primary
tumors growing beyond the rectal wall to an extent that precludes
primary surgical removal with sufficient margin. LARC patients are
commonly treated with neoadjuvant chemoradiotherapy (CRT) fol-
lowed by radical surgery. Major improvements in CRT and surgical
techniques the past decades have resulted in low local recurrence
rates [1]. Advancements are likely to build on these improvements
by developing even more precise treatment regimens with individ-
ualized neoadjuvant treatment schedules and organ-preserving
surgical approaches in selected patients, in order to improve out-
comes while preserving or increasing quality of life. A remaining
major challenge is that 30–40% of LARC patients experience poor
disease outcome due to metastatic progression [2]. At present,the idea of shifting current treatment paradigms to more individu-
alized approaches is controversial, with a major threat being the
lack of biomarkers enabling reliable treatment stratification. In this
regard, deciphering the biological tumor networks distinguishing
organ-confined from metastatic disease may lead to identification
of the critical biomarkers.
Individual tumors demonstrate considerable biologic hetero-
geneity as a result of ample variations in tumor microenvironmen-
tal features such as nutrient supply, pH and oxygenation,
developing as consequences of alterations in the metabolic and
proliferative status of tumor cells together with highly irregular
vascular structures [3,4]. Tumors’ unique metabolic phenotypes
result from altered substrate flux between and within major meta-
bolic pathways following their malignant transformation, due to
increased energy production (rapid ATP generation), increased
biosynthesis of macromolecules and tightened maintenance of
the cellular redox balance. Since shifts in tumor metabolic profiles
Table 1
Patient and tumor characteristics.
No. of patients 54
Gender
Male 35 (64.8%)
Female 19 (35.2%)
Median age (years)a 61 (31–73)
Male 61 (31–73)
Female 61 (38–70)
Median tumor volume at diagnosis (cm3)a 16.7 (1.1–293.4)
Disseminated tumor cells, DTCb
DTC positive 25 (46.3%)
DTC negative 19 (35.2%)
Not analyzed 10 (18.5%)
TNM stage at diagnosisc
T2 4 (7.4%)
T3 31 (57.4%)
T4 19 (35.2%)
N0 7 (13.0%)
N1 9 (16.6%)
N2 38 (70.4%)
394 Tumor glycine and rectal cancer outcomeare directly linked to their specific pathophysiology, such profiles
may be exploited in assessment of individual tumor aggressiveness
and metastatic propensity.
High-resolution magic angle spinning magnetic resonance spec-
troscopy (HR MAS MRS) is an established method for obtaining
metabolic profiles of tumor biopsies. Using this technique, we pre-
viously identified metabolic features related to microsatellite
instability in colon cancer [5], and compared metabolic profiles
of human colorectal carcinoma xenografts with human rectal
cancer biopsies [6]. Others have used HR MAS MRS for descriptive
purposes in colon and rectal cancer tissue, however, their main
focus has been to reveal differences between cancer tissue and
non-malignant tissue [7–10]. The use of HR MAS MRS to identify
metabolic markers of tumor aggressiveness and long-term thera-
peutic outcome in LARC remains largely unexplored.
We aimed to identify associations between pretreatment tumor
metabolic profiles and therapeutic outcome in a cohort of 54 LARC
patients with completed 5 years of follow-up after receiving
combined-modality neoadjuvant treatment and radical surgery.M0 50 (92.6%)
M1 4 (7.4%)
TN stage after neoadjuvant therapyd
ypT0 13 (24.1%)
ypT1 6 (11.1%)
ypT2 12 (22.2%)
ypT3 13 (24.1%)
ypT4 10 (18.5%)
ypN0 39 (72.2%)
ypN1 12 (22.2%)
ypN2 3 (5.6%)
Tumor regression grade, TRGe
1 (good response) 12 (22.2%)
2 (good response) 30 (55.6%)
3 (poor response) 5 (9.3%)
4 (poor response) 6 (11.1%)
5 (poor response) 1 (1.9%)
Follow-up resultsfMaterials and methods
Patients and treatment
The study protocol was approved by the Institutional Review
Board, The Regional Committee for Medical and Health Research
Ethics of South East Norway, and The NorwegianMedicines Agency.
The study was performed in accordance with the Helsinki
declaration, requiring written informed consent for participation.
Tumor biopsies from 54 patients enrolled between October 2005
and May 2008 were subjected to HR MAS MRS. Study eligibility cri-
teria are listed in Appendix A. Patient and tumor characteristics are
provided in Table 1. All patients received neoadjuvant chemother-
apy (NACT) followed by long-course CRT and surgery (details in
Appendix B).Local recurrence 2 (3.7%)
Metastatic disease 18 (33.3%)
Death 10 (18.5%)
Note: Except where indicated, data are numbers of patients, with percentages in
parentheses.
a Numbers in parentheses are ranges.
b Disseminated tumor cells in bone marrow were assessed by immunomagnetic
selection at the time of diagnosis.
c Assessed with magnetic resonance imaging or computed tomography according
to the tumor-node-metastasis system.
d Determined by histopathological evaluation of the surgical specimens.
e Tumor regression grade (TRG) is classified into good (TRG1–2) and poor
histologic response (TRG3–5).
f Censored at a median follow-up time of 64 months (range 3–66).Pretreatment tumor biopsies
At the time of diagnosis, 3–5 tumor biopsies were collected by
rigid proctoscopy, snap-frozen in liquid nitrogen and stored at
80 C. In order to assess tumor content in each biopsy, all biopsies
were embedded in tissue freeze medium (OTC) and one 4-lm
section was cut from the samples’ central part using a cryostat
microtome. The percentage of tumor cells in each section was
assessed after staining with hematoxylin and eosin (HE). To
include a biopsy in the metabolic profiling analysis we applied a
cut-off of 20% as the minimum required percentage of tumor cells.
For each patient, the biopsy with the highest tumor content
was selected. All patients had at least one sample with tumor
content >20%.Metabolic profiling of tumor biopsies
Tumor metabolic profiles were generated by HR MAS MRS [6].
The samples were prepared on an ice block within approximately
10 min. Sample preparation involved tissue cutting to remove
OTC and to fit the cylindrical MAS rotor (25 ll; mean sample
weight: 13.2 mg), and adding 3 ll phosphate buffered saline in
D2O containing formate and trimethylsilyl tetradeutero-propionic
acid (TSP). The HR MAS MR spectra were acquired on a Bruker
Avance DRX600 spectrometer equipped with a 1H/13C MAS probe
with gradient aligned with the magic angle axis (Bruker BioSpin
GmbH, Germany). Samples were kept at 4 C and spun at 5 kHz.
Magnet shimming provided optimized line shape and minimized
linewidth of formate (mean line width: 1.7 Hz).Electronic REference To access In vivo Concentrations (ERETIC)
single pulse spectra with water suppression were acquired for
quantification as previously published [11]. Briefly, spectrum
acquisition took 30 min for each sample. The raw spectral data
were multiplied with a 0.3 Hz exponential line broadening before
Fourier transformation and application of a second order linear
baseline correction. Peak areas were calculated using curve fitting
(PeakFit, Seasolve, USA). Metabolite tissue concentrations were
calculated from the areas relative to the ERETIC signal, the ERETIC
signals’ previously determined concentration, and the sample
weight, according to the PULCON principle [12].Histopathologic evaluation of profiled tumor biopsies
To ensure that the profiled tumor samples contained tumor
cells, all samples were subjected to histopathological evaluation.
First, the tissue was preserved in 10% formalin immediately after
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time from start of experiment to fixation was approximately 1 h.
One 5-lm section was cut from each paraffin block and stained
with HE. Tumor cell content was quantified by a pathologist with
12 years of experience, assuming the section to be representative
for the entire tissue sample.os
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Disseminated tumor cells (DTC) were analyzed by immunomag-
netic selection of mononuclear cells from bone marrow samples
aspired at the time of diagnosis [13] (Appendix C). Histopathologic
response evaluation of resected tumor specimens followed stan-
dardized procedures; ypTN staging and determination of histologic
tumor regression grade (TRG), ranging from pathologic complete
response (TRG1) to absence of regressive changes (TRG5) [14]. All
patients were scheduled to 5 years of follow-up after surgery and
the primary clinical endpoint was progression-free survival (PFS).
The follow-up results reported were censored on August 8, 2013.glu
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Fig. 1. Metabolite concentrations (lmol/g of tissue) in pretreatment tumor biopsies
analyzed with high-resolution magic angle spinning magnetic resonance spec-
troscopy. Each symbol represents individual patients’ metabolite concentration in
the analyzed tumor tissue.Statistical analysis
The one-sample Kolmogorov–Smirnov normality test revealed
that pretreatment tumor metabolite concentrations were non-
Gaussian distributed. Hence, data are presented as median and
range and analyzed usingnon-parametric tests. TheMann–Whitney
U test comparedmetabolic concentrations with TNM (T2–T3 versus
T4, N0 versus N1–2, M0 versus M1), DTC (DTC+ versus DTC), ypT
(ypT0–2 versus ypT3–4), ypN (N0 versus N1–2) and TRG (TRG1–2
versus TRG3–5). PFS was calculated from study enrollment until
date of diagnosis of local recurrence, distant metastasis, death of
any cause or end of follow-up. The performance of tumormetabolite
concentrations in prediction of PFSwas assessed by receiver operat-
ing characteristic (ROC) curves and calculation of sensitivity, speci-
ficity, positive-predictive value (PPV) and negative-predictive value
(NPV). From theROCcurve, the optimal cut-offwas identifiedbygiv-
ing equal weights to sensitivity and specificity (overall accuracy).
Univariate and multivariate Cox proportional hazard regression
analysis assessed associations between selected variables and PFS.
Variables appearing statistically significant in univariate Cox regres-
sion were entered into the multivariate analysis. Survival differ-
ences were assessed using the Kaplan–Meier method and log-rank
test. Patients with synchronous metastasis at the time of diagnosis
were omitted from PFS prediction. p-Values < 0.05 were considered
statistically significant. Multiple testing was accounted for by the
Benjamini–Hochberg method [15]. Statistical analysis was per-
formed in GraphPad Prism 6.0c for Mac OS X (GraphPad Software,
San Diego, CA).Results
Tumor metabolic profiles
Metabolic profiles were generated from all tumor biopsies. The
mean tumor cell content was 46.0 ± 15.2%. Some spectra contained
signals from the exploration gel used in the tumor biopsy sampling
procedure or the OTC freeze medium and ethanol used in sample
preparation. The spectral analysis was performed to minimize
the contributions from the contaminated signals, hence, we here
report on tissue concentrations of 10 metabolites that were reli-
ably identified; glucose, myo-inositol, glycine, taurine, choline,
phosphocholine, glycerophosphocholine, creatine, alanine and lac-
tate (Supplementary Table 1). Fig. 1 shows the tumor metabolite
concentrations.Metabolic profiles versus study endpoints
For the 10 quantified tumor metabolite concentrations, no sig-
nificant correlations to T, N, M, DTC, ypT, ypN or TRG were found.
For each metabolite, the cut-off concentration yielding the
highest accuracy for prediction of PFS was identified using ROC
analysis. High concentrations of glycine, creatine and myo-
inositol were associated with poor PFS. For glycine the highest
accuracy was obtained for a concentration of 1.77 lmol/g (area
under the ROC curve (AUC) = 0.70, 95% confidence interval (CI)
= 0.53–0.87, p = 0.028), yielding 71.4% sensitivity and 70.6% speci-
ficity, whereas for creatine the highest accuracy was found for a
concentration of 2.56 lmol/g (AUC = 0.65, 95% CI = 0.48–0.81,
p = 0.096), yielding 31.3% sensitivity and 94.1% specificity. For
myo-inositol the highest accuracy was detected for a concentration
of 2.86 lmol/g (AUC = 0.66, 95% CI = 0.49–0.83, p = 0.100), yielding
53.9% sensitivity and 78.8% specificity. In Fig. 2, differences in
patients’ PFS according to tumor glycine-, creatine- and myo-
inositol concentrations are visualized. When separating patients
above and below the identified cut-off values the respective
estimated 5-year PFS were 85% and 50% for glycine (p = 0.0038),
74% and 29% for creatine (p = 0.005) and 81% and 50% for
myo-inositol (p = 0.038).
Univariate Cox regression analysis revealed that high tumor
glycine-, creatine- and myo-inositol concentrations were signifi-
cantly associated with poor PFS, whereas no other pretreatment
variables were significantly associated with PFS (Table 2). The
association between adverse T stage (T4 versus T2–T3) and poor
PFS was close to significant (p = 0.055).
To identify the strongest pretreatment variable predicting poor
PFS, the two most significant metabolites, glycine and creatine, in
addition to the T stage, the most significant of assessed clinical
variables, were entered into multivariate regression analysis. From
this analysis, high tumor glycine concentration was identified as
the variable most significantly associated with poor PFS, with a
hazard ratio of 4.4 (95% CI = 1.4–14.3, p = 0.008) (Table 3).
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Fig. 2. Kaplan–Meier curves for progression-free survival for patients with low (blue) and high (green) concentrations of glycine (A), creatine (B) and myo-inositol (C) in the
analyzed tumor tissue, respectively. p-Values from the log-rank test are indicated.
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In this study, reporting on associations between pretreatment
tumor metabolic profiles and therapeutic outcome in LARC
patients receiving combined-modality neoadjuvant treatment fol-
lowed by radical surgery, we provide the first clinical evidence of
high tumor glycine concentration as an adverse prognostic factor.
Tumor glycine concentration remained the most significant predic-
tor of PFS in both univariate and multivariate analysis incorporat-
ing metabolic as well as routine clinical, pathological and
radiological parameters.
Glycine consumption and expression of the mitochondrial gly-
cine biosynthetic pathway have previously been shown to be
strongly associated with increased proliferation rates [16]. In Jain
et al., cellular consumption and release (CORE) profiles of 219
metabolites generated by mass spectrometry of media from the
NCI-60 panel of cancer cell lines demonstrated that glycine is con-
sumed by rapidly proliferating cells and released by slowly prolif-
erating cells. Further, antagonizing the glycine uptake and its
mitochondrial biosynthesis preferentially impaired the rapidly
proliferating cells. Clinical evidence of these findings have
remained invalidated, although the same study reported on higher
expression of the mitochondrial glycine metabolism enzymes ser-
ine hydroxymethyltransferase 2 (SHMT2) and methylenetetrahy-
drofolate dehydrogenases (NADP+ dependent) 2 and 1-like in
breast cancer as being associated with greater mortality. Based
on these findings it was proposed that tumors’ increased reliance
on glycine might represent a metabolic vulnerability for selectivelytargeting rapid cancer proliferation, and hence, a novel approach to
achieve therapeutic benefit in aggressive tumors.
When rapidly proliferating tumor cells outgrow their available
blood and nutrient supply, regions within the tumor become
hypoxic. Tumor hypoxia is a recognized major cause of tumor pro-
gression, metastasis development and treatment resistance in solid
cancers [17]. A recent report demonstrated that the SHMT2
enzyme was induced by hypoxia and that its expression was corre-
lated to both increased proliferation and unfavorable patient prog-
nosis [18]. Briefly, the function of the SHMT2 enzyme is to catalyze
the reversible reaction converting serine and tetrahydrofolate to
glycine and methylene-tetrahydrofolate, with the encoded product
primarily being responsible for glycine synthesis [19]. Glycine
along with other one-carbon units contribute to the purine and
thymidine synthesis required for nucleic acid synthesis and cell
proliferation [16,20]. Furthermore, mitochondrial reactive oxygen
species (ROS) levels are tightly regulated in cancer cells and a
steady-state level of ROS is required to allow cell proliferation
and activation of the hypoxia-inducible factor family of transcrip-
tion factors. By demonstrating that depletion of SHMT2 in hypoxic
cells increases ROS and induces cell death, Ye et al. proved that
SHMT2 is essential in NADPH production and ROS repression in
the mitochondria, contributing to maintain the necessary mito-
chondrial redox balance during hypoxia, and hence, continued
tumor cell survival and growth [18]. Hence, Ye et al. unveiled the
mitochondrial one-carbon metabolism as a promising pathway
for targeted cancer therapy, particularly for hypoxic tumors,
where, to date, available therapeutic options are limited.
Table 2
Univariate Cox proportional hazard regression analysis for progression-free survival.a
p HRb 95% CIb
Age
661 years
>61 years 0.323 1.7 0.6–4.6
Gender
Female
Male 0.672 0.8 0.3–2.2
Tumor volume
616.83 cm3
>16.83 cm3 0.187 2.0 0.7–5.6
CEA
64 ng/ml
>4 ng/ml 0.126 2.2 0.8–5.8
BMI
625 kg/m2
>25 kg/m2 0.496 0.71 0.26–1.9
T
T2–T3
T4 0.055 2.6 1.0–7.0
N
N
N+ 0.826 1.2 0.3–5.2
Glycine
Concentration < 1.77 lmol/g
Concentration > 1.77 lmol/g 0.009 4.7 1.6–15.2
Creatine
Concentration < 2.56 lmol/g
Concentration > 2.56 lmol/g 0.010 4.1 1.4–11.8
Myo-inositol
Concentration < 2.86 lmol/g
Concentration > 2.86 lmol/g 0.049 3.0 1.0–8.9
Bold signifies p-values < 0.05.
a Performed using the Cox proportional hazard regression model with backward,
stepwise elimination of variables.
b HR = hazard ratio, CI = confidence interval.
Table 3
Multivariate Cox proportional hazard regression analysis for progression-free
survival.a,b
p HRc 95% CIc
Glycine
Concentration < 1.77 lmol/g
Concentration > 1.77 lmol/g 0.008 4.4 1.4–14.3
T
T2–T3
T4 0.044 3.0 1.0–8.8
Bold signifies p-values < 0.05.
a Performed using the Cox proportional hazard regression model with backward,
stepwise elimination of variables.
b The following pretreatment variables were entered into the model: glycine
concentration, creatine concentration, T status.
c HR = hazard ratio, CI = confidence interval.
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our cohort, we performed Ki67 immunohistochemistry of tumor
samples analyzed with HRMASMRS (Appendix D), revealing a pos-
itive, but not significant, association between tumor glycine con-
centration and Ki67 labeling index (Supplementary Fig. 1). The
advanced disease manifestation of LARCs, commonly being
hypoxic and rapidly proliferating, as reflected by their high Ki67
indexes in our cohort, may indicate that tumor glycine concentra-
tion provides additional information on tumor aggressiveness
independent of their proliferation status, and thereby may
represent a superior marker for disease outcome.
Furthermore, it is shown that ROS and other components of the
one-carbon metabolism not only are essential for proliferation andtumorigenesis, but also play essential roles in the development of
metastasis [21]. Notably, in our investigated cohort the dominating
cause of PFS event was diagnosis of distant metastasis to the lung
and/or to the liver; in total 87.5% of the PFS events reported. The
remaining 12.5% were local recurrences. Hence, it may be relevant
to assess whether targeting of enzymes in the one-carbon metabo-
lism pathway diminishes the rate of metastasis. In addition, our
results motivate further investigations of the potential of tumor
glycine as early predictor of metastatic progression.
Current challenges in management of LARC are identification of
robust markers distinguishing organ-confined from metastatic dis-
ease, preferably early in the disease course that may aid implemen-
tation of more individualized therapies. Although metabolic
reprogramming has been regarded as essential for cancer cell pro-
liferation and proposed as a new hallmark of cancer, the systematic
characterization of activated metabolic pathways in aggressive
cancer is scarce. Recognizing the limited availability of therapeutic
options for highly proliferating and hypoxic tumors with poor
prognosis, inhibition of glycine influx or targeting of other central
components in the one-carbon metabolism may therefore
represent attractive approaches.
In our cohort routine clinical, pathological and radiological
parameters were uncorrelated or only weakly associated with
PFS. Hence, we believe the significant finding of tumor glycine con-
centration as adverse prognostic factor in our relatively small
cohort is strengthened. Compared to previous studies investigating
the expression of single enzymes in the one-carbon metabolism,
glycine concentration in tumor tissue analyzed by HR MAS MRS
is a fully quantitative measure of the end product. It is relevant
to notice that the quantified tumor metabolites showed no signif-
icant association to short-term surrogate markers of disease out-
come such as TRG, a commonly used short-term endpoint. This is
consistent with findings from locally advanced breast cancer,
where a decrease in glycine concentration after neoadjuvant treat-
ment was associated with long-term survival, although no associ-
ations to clinical response measures were identified [22]. Hence,
although surrogate endpoints may provide indications of disease
outcome, the results may reflect that long-term endpoints still
remain clinically superior.
When analyzing heterogeneous tissue biopsies with varying
amounts of tumor cells it may be challenging to interpret whether
the generated metabolic profiles are tumor-specific. However, our
previous work showed that tissue biopsies with tumor cell content
above 5% is sufficient to achieve a tumor-specific metabolic signa-
ture [23].
To summarize, we have by generating metabolic profiles of
pretreatment tumor biopsies from LARC patients receiving combined-
modality neoadjuvant treatment followed by radical surgery, provided
the first clinical evidence of high tumor glycine concentration as
adverse prognostic factor for PFS. Our attempts to identify a prop-
erly sized validation cohort, having collected both tumor tissue
samples at baseline and prospective recordings of long-term
outcome data, have unfortunately not been successful. However,
these initial results have generated new and intriguing hypotheses,
which motivate further investigations of glycine as an early
predictor of metastatic progression and therapeutic target.
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